Leszek Tylicki

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5036348/publications.pdf

Version: 2024-02-01

82 papers	1,059 citations	471509 17 h-index	501196 28 g-index
82 all docs	82 docs citations	82 times ranked	1063 citing authors

#	Article	IF	Citations
1	Predictors of Mortality in Hemodialyzed Patients after SARS-CoV-2 Infection. Journal of Clinical Medicine, 2022, 11, 285.	2.4	10
2	Analysis of Experiences in Preventing COVID-19 in Hemodialysis Centers of the North of Poland before the Era of Vaccination. International Journal of Environmental Research and Public Health, 2022, 19, 684.	2.6	3
3	SARS-CoV-2 infection in vaccinated maintenance hemodialysis patients despite anti-spike seroconversion: a report of 3 breakthrough cases. European Journal of Translational and Clinical Medicine, 2022, 5, 12-16.	0.1	3
4	Angiotensin Converting Enzyme Inhibitors May Increase While Active Vitamin D May Decrease the Risk of Severe Pneumonia in SARS-CoV-2 Infected Patients with Chronic Kidney Disease on Maintenance Hemodialysis. Viruses, 2022, 14, 451.	3.3	4
5	Changes in kidney graft function in COVID-19 convalescents.. Transplantation Proceedings, 2022, , .	0.6	1
6	Safety and tolerability of mRNA COVID-19 vaccines in kidney transplant recipients.. Transplantation Proceedings, 2022, , .	0.6	2
7	Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients. Transplantation Proceedings, 2022, , .	0.6	0
8	Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose. Vaccines, 2022, 10, 433.	4.4	10
9	Boosting Humoral Immunity from mRNA COVID-19 Vaccines in Kidney Transplant Recipients. Vaccines, 2022, 10, 56.	4.4	25
10	Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients. Archives of Medical Science, 2022, 18, 1100-1102.	0.9	2
11	Extremely high mortality in COVID-19 hemodialyzed patients in before anty-SARS-CoV-2 vaccination era. The first large database from Poland. Polish Archives of Internal Medicine, 2021, 131, 643-648.	0.4	16
12	Blood Pressure Control and Antihypertensive Treatment among Hemodialysis Patientsâ€”Retrospective Single Center Experience. Medicina (Lithuania), 2021, 57, 590.	2.0	2
13	Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project. Medicina (Lithuania), 2021, 57, 732.	2.0	23
14	Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19. The COViNEPH Project. Polish Archives of Internal Medicine, 2021, 131, 797-801.	0.4	12
15	Persistent Post-COVID-19 Syndrome in Hemodialyzed Patientsâ€”A Longitudinal Cohort Study from the North of Poland. Journal of Clinical Medicine, 2021, 10, 4451.	2.4	18
16	Humoral response to COVID-19 vaccination in patients treated with peritoneal dialysis: the COViNEPH Project. Polish Archives of Internal Medicine, 2021, 131, .	0.4	5
17	Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Studyâ€”The COViNEPH Project. Vaccines, 2021, 9, 1165.	4.4	38
18	Post-COVID-19 Sydrome and Decrease in Health-Related Quality of Life in Kidney Transplant Recipients after SARS-COV-2 Infectionâ€”A Cohort Longitudinal Study from the North of Poland. Journal of Clinical Medicine, 2021, 10, 5205.	2.4	14

#	Article	IF	Citations
19	Significant humoral response to mRNA COVID-19 vaccine in kidney transplant recipients with prior exposure to SARS-CoV-2. The COViNEPH Project. Polish Archives of Internal Medicine, 2021, , .	0.4	6
20	Gastrointestinal Pathologies in Patients After Successful Renal Transplantation. Transplantation Proceedings, 2020, 52, 2412-2416.	0.6	0
21	Improvement of Blood Pressure Control in Renal Transplant Recipientsâ€"Retrospective Longitudinal Study. Transplantation Proceedings, 2018, 50, 155-159.	0.6	4
22	Management of Renin-Angiotensin-Aldosterone System Blockade in Kidney Transplant Recipients. Transplantation Proceedings, 2018, 50, 1842-1846.	0.6	3
23	Treatment of Hypertension in Renal Transplant Recipients in Four Independent Cross-Sectional Analyses. Kidney and Blood Pressure Research, 2018, 43, 45-54.	2.0	11
24	The Schedule of Treatment and Control of Hypertension in Hemodialysis Patients and Renal Transplant Recipients in 2006 and 2014/2016. Transplantation, 2018, 102, S655.	1.0	0
25	Prevalence and Hypertension Treatment Schedule in Hemodialysis Patients and Renal Transplant Recipients in 2006 and 2014/2016. Transplantation Proceedings, 2018, 50, 1807-1812.	0.6	1
26	Dietary supplement use among patients with chronic kidney disease. Acta Biochimica Polonica, 2018, 65, 319-324.	0.5	3
27	Influence of Renin-Angiotensin System Blockers on Graft Function in Retrospective Analysis of Pairs of Renal Transplant Recipients From the Same Donor. Transplantation Proceedings, 2018, 50, 1838-1841.	0.6	1
28	Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Renal Transplant Recipients. Transplantation Proceedings, 2018, 50, 1834-1837.	0.6	2
29	Nonsteroidal anti-inflammatory drug use in patients with chronic kidney disease. Journal of Nephrology, 2017, 30, 781-786.	2.0	17
30	Aliskiren reduces albuminuria after kidney transplantation. Acta Biochimica Polonica, 2017, 64, 221-226.	0.5	4
31	Gastrointestinal Pathologies in Patients After Successful Renal Transplantationâ€"A Pilot Study. Transplantation Proceedings, 2016, 48, 1566-1569.	0.6	8
32	FP866ALISKIREN REDUCES ALBUMINURIA AFTER KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2015, 30, iii366-iii366.	0.7	0
33	Treatment of hypertension in chronic kidney disease patients under specialized care: One-center cross-sectional analyses. Blood Pressure, 2015, 24, 79-85.	1.5	7
34	Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 145-152.	1.7	8
35	Nephroprotective Action of Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease Patients: The Landscape After ALTITUDE and VA NEPHRON-D Trails. , 2015, 25, 194-200.		15
36	Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-Placebo controlled, randomized, cross-over study. Advances in Medical Sciences, 2014, 59, 256-260.	2.1	14

#	Article	IF	Citations
37	Dual blockade of the reninâ€“angiotensinâ€“aldosterone system in renal disease: what is the future? Authors' reply. Polish Archives of Internal Medicine, 2014, 124, 73-74.	0.4	0
38	Direct renin inhibition â€“ a promising strategy for renal protection?. Medical Science Monitor, 2013, 19, 451-457.	1.1	17
39	Safety of enhanced reninâ€“angiotensinâ€“aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Polish Archives of Internal Medicine, 2013, 123, 221-227.	0.4	4
40	Aliskiren and perindopril reduce the levels of transforming growth factor-Î² in patients with non-diabetic kidney disease. American Journal of Hypertension, 2012, 25, 636-639.	2.0	20
41	The Enhanced Renin-Angiotensin-Aldosteron System Pharmacological Blockade - Which is the Best?. Kidney and Blood Pressure Research, 2012, 36, 335-343.	2.0	14
42	Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial. International Urology and Nephrology, 2012, 44, 1763-1770.	1.4	17
43	Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions. Journal of Nephrology, 2012, 25, 900-910.	2.0	47
44	Letter to the Editor: Combination treatment and renal function in patients with chronic kidney disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2010, 11, 146-147.	1.7	0
45	Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.. Acta Biochimica Polonica, 2010, 57, .	0.5	19
46	Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.. Acta Biochimica Polonica, 2010, 57, .	0.5	6
47	Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial. American Journal of Kidney Diseases, 2008, 52, 486-493.	1.9	97
48	Dual blockade of the reninâ€“angiotensinâ€“aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: An open, controlled, randomized study. Scandinavian Journal of Urology and Nephrology, 2008, 42, 381-388.	1.4	7
49	The Effect of N-Acetylcysteine on Proteinuria and Markers of Tubular Injury in Non-Diabetic Patients with Chronic Kidney Disease. Kidney and Blood Pressure Research, 2008, 31, 404-410.	2.0	26
50	High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2008, 24, 689-690.	0.7	6
51	Effects of N-Acetylcysteine on Angiotensin-Converting Enzyme Plasma Activity in Patients with Chronic Kidney Diseases. Blood Purification, 2008, 26, 354-354.	1.8	2
52	Spironolactone Attenuates Oxidative Stress in Patients With Chronic Kidney Disease. Hypertension, 2008, 52, e132-3; author reply e134.	2.7	7
53	Addition of aldosterone receptor blocker to dual reninâ€“angiotensinâ€“aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney International, 2007, 72, 1164-1165.	5.2	16
54	Renal Allograft Protection with Angiotensin II Type 1 Receptor Antagonists L.. American Journal of Transplantation, 2007, 7, 243-248.	4.7	40

#	Article	IF	Citations
55	Randomized Placebo-Controlled Study on the Effects of Losartan and Carvedilol on Albuminuria in Renal Transplant Recipients. Transplantation, 2006, 81, 52-56.	1.0	26
56	Multifactoral analysis of determinators for renal injury in essential hypertension. Journal of Human Hypertension, 2006, 20, 93-95.	2.2	1
57	Blood Coagulation Unaffected by Ozonated Autohemotherapy in Patients on Maintenance Hemodialysis. Archives of Medical Research, 2006, 37, 1034-1037.	3.3	11
58	Smoking as a Risk Factor for Renal Injury in Essential Hypertension. Nephron Clinical Practice, 2006, 103, c121-c128.	2.3	12
59	Metabolic disturbances as strong determinator of kidney injury in essential hypertension. Journal of Hypertension, 2005, 23, 1433-1434.	0.5	3
60	Low-dose dual blockade of the reninâ€“angiotensin system improves tubular status in non-diabetic proteinuric patients. Scandinavian Journal of Urology and Nephrology, 2005, 39, 511-517.	1.4	9
61	Renal Protective Effects of the Renin-Angiotensin-Aldosterone System Blockade: From Evidence-Based Approach to Perspectives. Kidney and Blood Pressure Research, 2005, 28, 230-242.	2.0	35
62	Methylenetetrahydrofolate Reductase Gene Polymorphisms in Essential HypertensionRelation With the Development of Hypertensive End-Stage Renal Disease. American Journal of Hypertension, 2005, 18, 1442-1448.	2.0	10
63	Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis. Medical Science Monitor, 2005, 11, PI31-7.	1.1	3
64	Natural Killer Cell Activity Unaffected by Ozonated Autohemotherapy in Patients with End-Stage Renal Disease on Maintenance Renal Replacement Therapy. International Journal of Artificial Organs, 2004, 27, 766-771.	1.4	9
65	No effects of ozonated autohemotherapy on inflammation response in hemodialyzed patients. Mediators of Inflammation, 2004, 13, 377-380.	3.0	6
66	Tubulointerstitial injury: Early or late event in the pathogenesis of hypertensive nephropathy?. Kidney International, 2004, 65, 1971-1972.	5.2	3
67	Ozonated Autohemotherapy in Patients on Maintenance Hemodialysis: Influence on Lipid Profile and Endothelium. Artificial Organs, 2004, 28, 234-237.	1.9	21
68	Fistula Function and Dialysis Adequacy During Ozonotherapy in Chronically Hemodialyzed Patients. Artificial Organs, 2004, 28, 513-517.	1.9	5
69	Fistula Function and Dialysis Adequacy During Ozonotherapy in Chronically Hemodialyzed Patients. Artificial Organs, 2004, 28, 513-517.	1.9	5
70	Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. American Journal of Kidney Diseases, 2004, 43, 260-268.	1.9	56
71	Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. Scandinavian Journal of Urology and Nephrology, 2004, 38, 427-433.	1.4	26
72	Platelet function unaffected by ozonated autohaemotherapy in chronically haemodialysed patients. Blood Coagulation and Fibrinolysis, 2004, 15, 619-622.	1.0	3

#	Article	IF	Citations
73	Platelet function unaffected by ozonated autohaemotherapy in chronically haemodialysed patients. Blood Coagulation and Fibrinolysis, 2004, 15, 619-622.	1.0	2
74	Fistula function and dialysis adequacy during ozonotherapy in chronically hemodialyzed patients. Artificial Organs, 2004, 28, 513-7.	1.9	1
75	Ozonetherapy in a dialyzed patient with calcific uremic arteriolopathy. Kidney International, 2003, 64, 367-368.	5.2	13
76	Antioxidants: A Possible Role in Kidney Protection. Kidney and Blood Pressure Research, 2003, 26, 303-314.	2.0	53
77	Treatment of hypertension in renal transplant recipients. Current Opinion in Urology, 2003, 13, 91-98.	1.8	12
78	Tubular injury: the first symptom of hypertensive kidney involvement?. Medical Science Monitor, 2003, 9, CR135-41.	1.1	9
79	Multifactorial Determination of Hypertensive Nephroangiosclerosis. Kidney and Blood Pressure Research, 2002, 25, 341-353.	2.0	16
80	Renoprotective Effect of Small Doses of Losartan and Enalapril in Patients with Primary Glomerulonephritis. American Journal of Nephrology, 2002, 22, 356-362.	3.1	47
81	Short-term effects of angiotensin II receptor blockade in patients with primary glomerulonephritis: Pilot study. , 2002, 12, 122-125.		5
82	Hypertensive Nephropathy â€“ An Increasing Clinical Problem. Mineral and Electrolyte Metabolism, 1999, 25, 65-68.	1.1	20